Mark Jacobson
Chief Operating Officer chez AXSOME THERAPEUTICS, INC.
Fortune : - $ au 31/03/2024
Profil
Mark L.
Jacobson is currently the Chief Operating Officer at Axsome Therapeutics, Inc. He previously worked as the Director of Corporate Development at Stemline Therapeutics, Inc. from 2009 to 2014.
Mr. Jacobson received his graduate degree from The Trustees of Columbia University in The City of New York in 2010 and his undergraduate degree from Iowa State University in 2006.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/04/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Mark Jacobson
| Sociétés | Poste | Début |
|---|---|---|
| AXSOME THERAPEUTICS, INC. | Chief Operating Officer | 01/04/2014 |
Anciens postes connus de Mark Jacobson
| Sociétés | Poste | Fin |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/03/2014 |
Formation de Mark Jacobson
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| Iowa State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AXSOME THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
